January 12, 2018 / 4:58 PM / Updated 6 minutes ago BRIEF-ICER Says Spark Therapeutics Gene Therapy Price Too High Reuters Staff 1 Min Read 
Jan 12 (Reuters) - Spark Therapeutics Inc: 
* INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW SAYS SPARK THERAPEUTICS LUXTURNA GENE THERAPY PRICE FAR TOO HIGH 
* ICER SAYS $850,000 PRICE FOR LUXTURNA BLINDNESS TREATMENT SHOULD BE 75-82 PERCENT LOWER BASED ON VALUE ASSESSMENT 
* ICER RECOMMENDS LUXTURNA PRICE BETWEEN $153,000 AND $217,000 FOR ONE-TIME GENE THERAPY Source text for Eikon: Further company coverage: (Reporting By Bill Berkrot)